Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ABBV

3 Healthcare ETFs to Buy for Defensive Growth in 2024

Healthcare ETFs hold the potential for higher returns, diversification, and exposure to stably growing companies. Therefore, it could be wise to invest in robust healthcare ETFs like iShares U.S. Healthcare Providers ETF (IHF), Vanguard Health Care Index Fund ETF Shares (VHT), and Health Care Select Sector SPDR Fund (XLV) for…

StockNews.com

3 High-Dividend Pharma Blue Chips That Are on Sale Right Now

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the market. Amid this backdrop, it could be wise to scoop up the shares of fundamentally sound pharma stocks like AbbVie (ABBV), Novartis (NVS), and Pfizer (PFE), which are not just…

StockNews.com

3 Healthcare Stocks Benefiting From Aging Populations

The healthcare industry is thriving, owing to the growing healthcare expenditure and aging population. Given the industry’s tailwinds, fundamentally sound healthcare stocks AbbVie (ABBV), Boston Scientific (BSX), and CVS Health (CVS) could be solid buys. Keep Reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

3 Healthcare Stocks With Strong Buy Ratings

The healthcare sector is proving to be a robust investment haven, particularly as it continues to evolve with groundbreaking technology and strong government support. Therefore, adding strong A-rated stocks like Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK) could help garner significant returns. Read more….

StockNews.com

3 Defensive Dividend Stocks to Scoop Up Now

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

Barchart

3 Bargain Healthcare Stocks to Buy for Long-Term Gains

The healthcare sector is poised for significant growth, driven by advancements in drug development, ongoing research and development (R&D) efforts, and its ability to remain resilient even during economic downturns. Thus, investors might consider buying bargain pharma stocks: Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) for…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Must-Buy Healthcare Stocks for Defensive Investing

The healthcare sector is set for significant growth due to advancements in pharma technology, increasing demand for personalized medicines, and resilience even in economic downturns. Therefore, investors might consider buying quality pharmaceutical stocks like Pfizer (PFE), Johnson & Johnson (JNJ), and AbbVie (ABBV) for defensive investing. Read on.

StockNews.com

What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

Secure Decades of Passive Income: 3 Top Dividend Stocks to Buy Now

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

Barchart

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the aging population. Hence, quality healthcare stocks, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK), might be worth looking into. Read more….

StockNews.com

Option Volatility And Earnings Report For July 22 - 26

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

Barchart

AbbVie Earnings Preview: What to Expect

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Barchart

3 Healthcare Stocks With Strong Profit Margins to Buy Now

The healthcare industry is poised to grow rapidly due to the rising need for medical aid, government initiatives, and increasing chronic diseases contributing to overall stability. Given the industry’s promising prospects, investors could consider buying quality healthcare stocks: UnitedHealth Group (UNH), Johnson & Johnson (JNJ), and AbbVie (ABBV), with strong…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Undervalued Healthcare Stocks With High Potential

The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read…

Barchart

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Barchart

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Barchart

Abbvie Stock: Is Wall Street Bullish or Bearish?

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

Barchart

3 Defensive Stocks for 'Sell in May' Season

Investors can consider adding defensive stocks, such as AbbVie and Verizon, to their equity portfolios in 2024 to help shield against heightened stock market volatility.

StockNews.com

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

StockNews.com

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

Barchart

The Best of the Best: The Top Dividend Aristocrats To Buy Now

Looking to add dividend aristocrats to your portfolio? These three are at the top of their game.

StockNews.com

Unleash Gain Potential With 3 Pharma Stocks to Consider

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

1 … 3 4 5 6

People

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.